Clinical trials: Patients with Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone supplement (cholecalciferol). Low levels of Vitamin D have been described to be associated with a higher risk of developing Multiple…
- Trial name
- SOLAR (NCT01285401)
- Testing
- VigantOL oil plus interferon beta-1a (Rebif), Interferon beta-1a (Rebif®) alone
- Where
- 38 sites in Austria, Denmark and 10 more
- Volunteers
- 260 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis (RRMS)
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- RED4MS (NCT06430671)
- Testing
- CLS12311 low, CLS12311 medium, CLS12311 high
- Where
- 8 sites in Czechia, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Cellerys AG
Multiple Sclerosis
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
Patients who have been diagnosed with clinically isolated syndrome (CIS) often develop problems related to the central nervous system, which controls the nerves in the body.
- Trial name
- STAYCIS (NCT00094172)
- Testing
- Atorvastatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis Relapse
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
The primary objective was to demonstrate the effect of teriflunomide, in comparison to placebo, on frequency of Multiple Sclerosis (MS) relapses in patients with relapsing forms of MS who are treated with Interferon-beta…
- Trial name
- TERACLES (NCT01252355)
- Testing
- Teriflunomide, Interferon-beta (IFN-beta)
- Where
- 185 sites in United States, Argentina and 26 more
- Volunteers
- 534 people
- Sponsor
- Sanofi
Multiple Sclerosis
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis [MS].
- Trial name
- TENERE (NCT00883337)
- Testing
- Interferon β-1a, Teriflunomide
- Where
- 54 sites in Belgium, Canada and 11 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS.
- Trial name
- NCT03085810
- Testing
- Ocrelizumab
- Where
- 193 sites in United States, Argentina and 27 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Cerebral Palsy, Multiple Sclerosis
Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery
The purpose of this study is to record signatures from the fluid surrounding the spinal cord from people who have an implanted drug infusion system.
- Conditions
- Cerebral Palsy, Multiple Sclerosis, Traumatic Brain Injury, Spinal Cord Injury
- Trial name
- NCT01117090
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- MedtronicNeuro
Epilepsy, Dravet Syndrome
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- ELEKTRA (NCT03650452)
- Testing
- TAK-935
- Where
- 44 sites in United States, Australia and 6 more
- Volunteers
- 141 people
- Sponsor
- Takeda
Relapsing Forms of Multiple Sclerosis
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal (GI)-related events reported by participants with relapsing forms of multiple sclerosis (MS) initiating therapy with…
- Trial name
- MANAGE (NCT01873417)
- Testing
- BG00012 (DMF)
- Where
- 37 sites in United States
- Volunteers
- 237 people
- Sponsor
- Biogen
Parkinson's Disease, Multiple Sclerosis
Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients
Fatigue is one of the most common and debilitating symptoms experienced in Parkinson's Disease (PD) and Multiple Sclerosis (MS).
- Trial name
- PDMSLac (NCT02184494)
- Testing
- pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Florida State University
Epilepsy, Tuberous Sclerosis Complex
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
The goal of this study is to learn if the study drug RAD001 can reduced the number of epileptic seizures, and can be taken safety by people who have epilepsy associated with Tuberous Sclerosis Complex.
- Trial name
- NCT01070316
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Multiple Sclerosis
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
The aim of this multicentre, randomised, double-blind, placebo-controlled study is to evaluate the efficacy and safety of supplementary treatment with cholecalciferol (vitamin D3) in subjects with relapsing multiple sclerosis (R…
- Trial name
- CHOLINE (NCT01198132)
- Testing
- Cholecalciferol (Vitamin D3), Rebif
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
The aim of this study is to study the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate) or placebo for 6 months on immune system and Th1/Th2 balance in patients with Multiple…
- Trial name
- NCT01225289
- Testing
- Vitamin A
- Where
- 2 sites in Iran
- Volunteers
- 36 people
- Sponsor
- Tehran University of Medical Sciences
Multiple Sclerosis
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
This is an open-label, multicenter study conducted at approximately 20 sites. Each patient will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall injection satisfaction.
- Trial name
- ENCORE (NCT01167426)
- Testing
- Glatiramer Acetate 20 mg/0.5 mL
- Volunteers
- 148 people
- Sponsor
- Teva Neuroscience, Inc.
Multiple Sclerosis
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
The primary objective of this study was to document the long-term safety and tolerability of teriflunomide in Multiple Sclerosis (MS) participants with relapse.
- Trial name
- NCT00803049
- Testing
- Teriflunomide (HMR1726)
- Where
- 116 sites in United States, Austria and 19 more
- Volunteers
- 742 people
- Sponsor
- Sanofi
Relapsing-remitting Multiple Sclerosis (RRMS)
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
- Trial name
- ASSESS (NCT01633112)
- Testing
- fingolimod, glatiramer acetate
- Where
- 130 sites in United States, Argentina and 5 more
- Volunteers
- 1,064 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and…
- Trial name
- Beyond (NCT00459667)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 184 sites in United States, Argentina and 24 more
- Volunteers
- 1,420 people
- Sponsor
- Bayer
Relapsing Forms of Multiple Sclerosis
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease…
- Trial name
- EPOC (NCT01216072)
- Testing
- Fingolimod, Standard MS DMTs
- Where
- 149 sites in United States, Canada and 1 more
- Volunteers
- 1,053 people
- Sponsor
- Novartis Pharmaceuticals
TSC1, TSC2
Everolimus for Cancer With TSC1 or TSC2 Mutation
In this research study, the investigators are evaluating the clinical benefit of everolimus in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations.
- Conditions
- TSC1, TSC2, Tuberous Sclerosis Complex, MTOR
- Trial name
- NCT02201212
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Sclerosis, Depression
Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis
This study will determine whether fish oil can reduce depression in people with multiple sclerosis (MS) who are mild to moderately depressed and are currently taking antidepressant medication.
- Trial name
- NCT00122954
- Testing
- Fish oil concentrate
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Oregon Health and Science University